Related Experiment Video
Updated: Jul 15, 2026
08:02
Generation of Local CA1 γ Oscillations by Tetanic Stimulation
Published on: August 14, 2015
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures
R J Porter1, A Partiot, R Sachdeo
1University of Pennsylvania, Philadelphia, PA, USA. rjportermd@aol.com
Neurology
|April 11, 2007
Summary
Retigabine, an adjunctive therapy, effectively reduces partial-onset seizure frequency in a dose-dependent manner. This study found retigabine well-tolerated, offering a new treatment option for epilepsy patients.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Partial-onset seizures represent a significant challenge in epilepsy management.
- Identifying effective adjunctive therapies is crucial for improving seizure control.
Purpose of the Study:
- To assess the efficacy and safety of retigabine as adjunctive therapy for partial-onset seizures.
- To determine the dose-response relationship of retigabine in reducing seizure frequency.
Main Methods:
- A multicenter, randomized, double-blind, placebo-controlled trial.
- Patients received retigabine (600, 900, or 1,200 mg/day) or placebo as adjunctive therapy.
- Efficacy measured by change in monthly seizure frequency and responder rates; safety assessed via adverse events.
Main Results:
- Retigabine demonstrated a dose-dependent reduction in partial-onset seizure frequency compared to placebo (p < 0.001).
- Responder rates (>/=50% seizure reduction) were significantly higher with retigabine (23-33%) versus placebo (16%).
- Common adverse events included somnolence, dizziness, and confusion.
Conclusions:
- Adjunctive retigabine is effective in reducing partial-onset seizures.
- The treatment is well-tolerated and shows a dose-dependent efficacy profile.
- Retigabine offers a viable therapeutic option for patients with refractory partial-onset epilepsy.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...